Xenon Pharmaceuticals (XENE) Expected to Announce Quarterly Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.89) per share and revenue of $0.31 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Xenon Pharmaceuticals Price Performance

XENE stock opened at $37.65 on Wednesday. The company has a 50 day moving average price of $39.39 and a 200 day moving average price of $40.35. Xenon Pharmaceuticals has a fifty-two week low of $35.53 and a fifty-two week high of $50.99. The stock has a market capitalization of $2.87 billion, a PE ratio of -13.35 and a beta of 1.20.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on XENE shares. Needham & Company LLC restated a “buy” rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus price target of $57.38.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 16,315 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the sale, the chief executive officer now owns 31,302 shares in the company, valued at $1,267,731. This represents a 34.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,492 shares of company stock worth $2,334,969. Insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.